Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Docusign Inc (DOCU) vs ResMed Inc. (RMD) Price & Performance

Docusign IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Docusign Inc vs ResMed Inc. — how do they compare? Docusign Inc trades at $59.01 (market cap $11.39B), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: ResMed Inc. is far larger — about 2.8× Docusign Inc's market cap, and ResMed Inc. pays a 1.2% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.

DOCURMD
Market Cap
$11.39B$31.92B
Sector
TechnologyHealth
52-Week High
$85.01$293.73
52-Week Low
$41.75$182.82
Enterprise Value
$10.76B$31.28B
Dividend Yield
1.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Docusign Inc

DOCU trades at $60.26, up 5.91% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support at $58 and resistance at $61. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. Analyst consensus is mixed with a $55.40 price target below the current price, indicating caution despite recent strength.

Outlook balances robust profitability and growth against high valuation and cash flow concerns. The stock offers upside if earnings momentum continues but faces risks from competitive pressures and reliance on subscription renewals. Institutional activity shows mixed signals with some funds reducing stakes.

ResMed Inc.

ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.

Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.

Returns comparison

Trailing returns across standard periods

About Docusign Inc

DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.

Read more on DOCU

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD